Navigation Links
Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic
Date:12/14/2009

er's expectation that the sale of XenBio to Taconic is expected to have minimal impact on Caliper's bottom-line performance and operating cash flows in 2010, and Caliper's fourth quarter revenue guidance, are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors. Further information on risks faced by Caliper are detailed under the caption "Risks Related To Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2008. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release.

SOURCE Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
2. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
3. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
4. Caliper Awarded New Task Order for EPA ToxCast Program
5. Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... 21, 2014  CASI Pharmaceuticals, Inc. (Nasdaq: ... the treatment of cancer and other diseases, announced today ... Administration (CFDA) has approved the Company,s application to conduct ... (TNBC) patients in China for ... Ken K. Ren , Ph.D., CASI,s Chief Executive Officer, ...
(Date:7/21/2014)... , July 22, 2014 Research and ... of the "Global Coronary Stents Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 A coronary stent is a ... of stainless steel, cobalt-based alloy with mechanism of ... blockages that may occur in patients after they ...
(Date:7/18/2014)... July 18, 2014  Patient engagement is a ... marketing is one of the principal groups that ... Policy groups within the pharmaceutical industry are among ... activities and initiatives to positively impact the "patient ... firm, Best Practices, LLC, identified the key support ...
Breaking Medicine Technology:CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 4Global Coronary Stents Market 2014-2018: Key Vendors are Abbott, Boston Scientific, Medtronic and Terumo 2Global Coronary Stents Market 2014-2018: Key Vendors are Abbott, Boston Scientific, Medtronic and Terumo 3Government Affairs & Public Policy Groups Playing Critical Role in Patient Engagement, Reports Best Practices, LLC 2
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President and ... Sachs Global Healthcare Conference on Tuesday, June 15 , at ... Los Angeles .  The presentation will be webcast on the following ... , ...
... Epocal, Inc., a leading edge provider of point ... Food and Drug Administration (FDA) clearance to market its new ... from the epoc System are used to evaluate acid-base status ... acidity of the blood).  The addition of lactate to the ...
Cached Medicine Technology:Epocal Announces FDA Clearance of Lactate Test 2
(Date:7/22/2014)... Bar, CA (PRWEB) July 22, 2014 ... leading provider of enterprise Time and Attendance / ... in Iowa, a NOVAtime 3000 customer since 2007, ... self-hosted, licensed version of NOVAtime’s state-of-the-art, web-based time ... Lutheran Services in Iowa (LSI) is a human ...
(Date:7/22/2014)... Orem, UT (PRWEB) July 22, 2014 Most people ... first is a weak appetite and the second is a fast ... CB-1 Weight Gainer provides ways to help fight these ... lack of appetite. There are people out there who just can’t ... take bites and then they are full. The cause of this ...
(Date:7/21/2014)... designed to target and kill cancer cells could boost ... and help avoid amputation, a new study reports. , ... the effectiveness of a genetically engineered version of the ... use of the virus alongside isolated limb perfusion chemotherapy ... arm or leg as an alternative to amputation ...
(Date:7/21/2014)... July 22, 2014 iFitDress.com, a famous ... women, has announced its exclusive collection of 2014 ... a promotion for its brand new gowns. , iFitDress.com ... the current market. Its sales boomed in the recent ... products, but also because of the amicable services offered ...
(Date:7/21/2014)... July 21, 2014 The League of ... 1199SEIU United Healthcare Workers East (“1199SEIU”) today announced a ... issues facing healthcare providers and their employees. , ... require ratification by League and 1199SEIU members, employee wages ... addition, all existing worker benefits, including healthcare coverage with ...
Breaking Medicine News(10 mins):Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CB-1 Weight Gainer Provides Two Tips to Help Customers Gain Weight 2Health News:Viral therapy could boost limb-saving cancer treatment 2Health News:Viral therapy could boost limb-saving cancer treatment 3Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2Health News:League of Voluntary Hospitals and Homes and 1199SEIU Reach New Four-Year Collective Bargaining Agreement 2Health News:League of Voluntary Hospitals and Homes and 1199SEIU Reach New Four-Year Collective Bargaining Agreement 3
... 11 (HealthDay News) -- Low oxygen supply (hypoxia) increases the ... a severe traumatic brain injury (TBI), a new study finds. ... with TBI, most of whom had bleeding within the brain ... fared poorly, suffering severe disability, dying or being in a ...
... SAN FRANCISCO, CA NOVEMBER 11, 2011 ... demonstrated that cryoplasty post-dilitation compared to conventional balloon ... the risk of in-stent restenosis (ISR). Results from ... the 23rd Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific ...
... FRIDAY, Nov. 11 (HealthDay News) -- Repeated bouts of ... pain and infertility, a new study says. Pelvic inflammatory ... is marked by inflammation of the reproductive organs. The condition ... year and one in 10 of them becomes infertile, according ...
... SAN FRANCISCO, CA NOVEMBER 11, 2011 ... de novo coronary artery lesions showed a significantly ... to paclitaxel-eluting stents with permanent polymers. ... at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) ...
... the past 100 years, the Haber-Bosch process has been used ... the manufacture of fertilizer. Despite the longstanding reliability of the ... works. But now a team of chemists, led by Patrick ... how the ammonia is formed. Their findings are published in ...
... FRIDAY, Nov. 11 (HealthDay News) -- Age-related declines in ... to a new study. "The more income and ... be," co-author Virginia Richardson, a professor of social work ... release. The researchers analyzed data from roughly 6,500 ...
Cached Medicine News:Health News:Results of the COBRA trial reported at TCT 2011 2Health News:STD Complication May Double Infertility Risk 2Health News:Results of the NEXT clinical trial Reported at TCT 2011 2Health News:Researchers gain insight into 100-year-old Haber-Bbosch process 2
Each handle is designed to fit a specific trephine size....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: